PT  - JOURNAL ARTICLE
AU  - MIOKO MATSUO
AU  - KAZUKI HASHIMOTO
AU  - RYUNOSUKE KOGO
AU  - RINA JIROMARU
AU  - TAKAHIRO HONGO
AU  - TOMOMI MANAKO
AU  - TAKASHI NAKAGAWA
TI  - Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies
AID  - 10.21873/invivo.13312
DP  - 2023 Sep 01
TA  - In Vivo
PG  - 2147--2154
VI  - 37
IP  - 5
4099  - http://iv.iiarjournals.org/content/37/5/2147.short
4100  - http://iv.iiarjournals.org/content/37/5/2147.full
SO  - In Vivo2023 Sep 01; 37
AB  - Background/Aim: In recent years, individual patient cancer genomic profiling (CGP) has become more accessible, allowing determination of therapeutic strategies using driver gene mutations in cancer therapy. However, this precision oncology approach, tailored to specific patients, remains experimental. In this study, we verified the feasibility and benefit of using CGP to guide treatment of malignant head and neck tumors. We aimed to evaluate the profiling and clinical courses of patients with head and neck malignancies who underwent CGP and determine the extent to which CGP for head and neck malignancies has resulted in beneficial drug administration. Patients and Methods: We analyzed CGP results, prognosis, and drug administration status in 27 patients. These patients had completed (or were expected to complete) standard therapy or had rare cancers without standard therapy. Results: At least one somatic actionable gene alteration was seen in 25 (92.6%) patients, with a median number of actionable alterations per patient of 4 (range=0-11). Drugs in clinical trials were recommended to 22 (81.5%) patients, but none could participate. However, 3 patients (11.1%) could use approved drugs off-label based on CGP results. The most common genetic abnormality was TP53 (66.7%), with TP53 mutations leading to poor prognosis. Conclusion: CGP is clinically useful and serves as a bridge to increase the number of therapeutic options. However, candidate drugs confirmed using CGP may be ineffective when administered. Therefore, oncologists should not blindly accept CGP therapeutic recommendations but should make recommendations that lead to optimal therapies after proper verification.